Arteriovenous Fistula – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Arteriovenous
fistulas (AVFs) denote abnormal connections between an artery and a vein,
sometimes referred to as arteriovenous malformations. These anomalies can
manifest throughout the body, depending on the underlying cause. AVFs are
categorized into acquired or congenital forms, arising either from surgical
creation for hemodialysis access, congenital anomalies, or secondary to
iatrogenic injury or trauma. Duplex ultrasound (US) is a non-invasive and
cost-effective means to confirm AVF diagnosis, mainly when the AVF is
superficial. However, early intervention is now used to prevent avoidable
complications, particularly in post-traumatic AVFs, which should be promptly
addressed upon diagnosis. The primary objective of AVF treatment is to isolate
and close the fistula while preserving essential blood flow. Stent grafts are
commonly employed to exclude the fistula while maintaining vascular integrity,
whereas coils may be utilized when embolizing essential vessels poses minimal
risk. Various sclerosing agents, such as injectable absolute ethanol, are among
the therapeutic options available for AVF treatment.
Thelansis’s “Arteriovenous Fistula Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2023 To 2033" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Arteriovenous
Fistula treatment modalities options for eight major markets (USA, Germany,
France, Italy, Spain, UK, Japan, and China).
KOLs insights of Arteriovenous Fistula across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Arteriovenous Fistula Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment